Intravenous immunoglobulin for Alzheimer's disease

The Lancet Neurology

Volumn 12, Issue 3, 2013, Pages 218-219

  Holmes, Clive ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BAPINEUZUMAB; IMMUNOGLOBULIN; PLACEBO; SOLANEZUMAB;

ALZHEIMER DISEASE; HUMAN; LETTER; PRIORITY JOURNAL; FEMALE; IMMUNOLOGY; MALE; NOTE;

ALZHEIMER DISEASE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE;

MLCS; MLOWN;

EID: 84876301844     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70015-2     Document Type: Letter

References (6)

1. Solomon B Intravenous immunoglobulin and Alzheimer's disease immunotherapy. Curr Opin Mol Ther 2007, 9:79-85.
2. Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 2012, 8:261-271.
3. Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004, 75:1472-1474.
4. Relkin NR, Szabo P, Adamiak B, et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009, 30:1728-1736.
5. Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's Disease: a phase 2, randomised, double-blind, placebo-controlled dose-finding trial. Lancet Neurol 2013, published online Jan 31. http://dx.doi.org/10.1016/S1474-4422(13)70014-0.
6. Vellas B, Black R, Thal LJ, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009, 6:144-151.